GT Healthcare Capital Partners launches AI-driven drug development company

The Union Cabinet has given approval to the three MoUs signed between India and Gambia, Republic of Guinea, the National Institute of Health (NIH) of the Ministry of Health of the Republic of Peru for cooperation in the field of traditional systems of medicine. The MoUs were signed in Gambia on July 31, 2019 and in Guinea on August 2, 2019 during President of India Ram Nath Kovind visit in the respective countries. The initiatives taken by the three countries will be as per the terms of reference of the MoU signed and will be a continuing process till the MoU remains in operation. The MoU will enhance bilateral cooperation between the three countries in the areas of traditional systems of medicine. This will be of immense importance to all the countries considering their shared cultural heritage. As a part of the MoU of Gambia, there will be exchange of experts for training of the practitioners and scientists undertaking collaborative research in traditional systems of medicine. This is going to lead to new innovations in drug development and practice of traditional medicine. Keeping in view of the need for promotion and propagation of Ayush systems of medicine in Guinea, standard draft MoU for cooperation in the field of traditional medicine and homoeopathy was shared with the Guinean side through Central and West Africa Division, Ministry of External Affairs. As a part of the MoUs, the financial resources necessary to conduct research, training courses, conferences, meetings and deputations of experts will be met from the existing allocated budget and existing plan schemes of Union Ayush Ministry.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!